1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating tomedicinal products for human use (OJ L 311, 28.11.2001, p. 67) as amended (consolidated version 30/12/2008) [online]. Available from URL:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20081230:EN:PDF
[Accessed 2010 Jul 23]
2. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1) [consolidated version: 20/04/2009
3. online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726_cons/reg_2004_726_cons_en.pdf [Accessed 2010 Jul 23]
4. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on compassionate use of medicinal products, pursuant to article 83 of Regulation (EC) No 726/2004 [online]. Available from URL:
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004075.pdf
[Accessed 2010 Aug 16]
5. European Medicines Agency. Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to Member States for IV Tamiflu: available for compassionate use [online]. Available from URL:
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/05/WC500090250.pdf
[Accessed 2010 Jul 23]